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Article abstract—Autism is a common disorder of childhood, affecting 1 in 500 children. Yet, it often remains 
unrecognized and undiagnosed until or after late preschool age because appropriate tools for routine developmental 
screening and screening specifically for autism have not been available. Early identification of children with autism and 
intensive, early intervention during the toddler and preschool years improves outcome for most young children with 
autism. This practice parameter reviews the available empirical evidence and gives specific recommendations for the 
identification of children with autism. This approach requires a dual process: 1) routine developmental surveillance and 
screening specifically for autism to be performed on all children to first identify those at risk for any type of atypical 
development, and to identify those specifically at risk for autism; and 2) to diagnose and evaluate autism, to differentiate 
autism from other developmental disorders.  
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Table Diagnostic Criteria for 299.00 Autistic Disorder 
A. A total of six (or more) items from (1), (2), and (3), with two from (1), and at least one each from (2) and (3): 
1. Qualitative impairment in social interaction, manifest by at least two of the following: 
• Marked impairment in the use of multiple nonverbal behaviors, such as eye-to-eye gaze, facial expression, body postures, and gestures, 
to regulate social interaction 
• Failure to develop peer relationships appropriate to developmental level 
• Lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (e.g., by lack of showing, bringing, or 
pointing out objects of interest) 
• Lack of social or emotional reciprocity 
2. Qualitative impairment in communication, as manifest by at least one of the following: 
• Delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate through alternative 
modes of communication such as gesture or mime) 
• In individuals with adequate speech, marked impairment in the ability to initiate or sustain a conversation with others 
• Stereotyped and repetitive use of language, or idiosyncratic language 
• Lack of varied, spontaneous make-believe, or social imitative play appropriate to developmental level 
3. Restrictive repetitive and stereotypic patterns of behavior, interests, and activities, as manifested by at least one of the following: 
• Encompassing preoccupation with one or more stereotyped and restricted patterns of interest that is abnormal either in intensity or 
focus 
• Apparently inflexible adherence to specific nonfunctional routines or rituals 
• Stereotyped and repetitive motor mannerisms (e.g., hand or finger flapping or twisting, or complex whole-body movements) 
• Persistent preoccupation with parts of objects. 
B. Delays or abnormal functioning in at least one of the following areas, with onset prior to age 3 years: 
1. Social interaction 
2. Language as used in social communication 
3. Symbolic or imaginative play 
C. The disturbance is not better accounted for by Rett’s disorder or childhood disintegrative disorder. 
 
The other pervasive developmental disorders include Asperger’s disorder, Rett syndrome, childhood disintegrative disorder, pervasive developmental 
disorder—not otherwise specified (PDD-NOS), or atypical autism. 
 
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Washington, DC: American Psychiatric 
Association, 1994:70-71. 
Detailed information on other PDD diagnoses can be found in the comprehensive background paper.1 
NEUROLOGY 2000;55:468-479 
 
Autism, autistic spectrum, and pervasive developmental disorders encompass a wide continuum of associated cognitive 
and neurobehavioral disorders, including the core-defining features of impaired socialization, impaired verbal and 
nonverbal communication, and restricted and repetitive patterns of behavior (table).1 Between 60,000 and 115,000 
children under 15 years of age in the United States meet diagnostic criteria for autism based on recent prevalence 
estimates of 10 to 20 cases per 10,000 people. In 1,300 families recently surveyed, the average age at diagnosis of autism 
was about 6 years, despite the fact that most parents felt something was wrong by 18 months of age and usually sought  
medical assistance by age 2 years.2 Fewer than 10% of the children were diagnosed at initial presentation; another 10% 
were either told to return if their worries persisted, or that their child "would grow out of it." The rest were referred to 
another professional (at a mean age of 40 months), of which only 40% were given a formal diagnosis, 25% were told "not 
to worry," and 25% were referred to a third or fourth professional. Almost 20% reported that they either had to exert 
considerable pressure to obtain the referrals or pay privately. Over 30% of parents referred to subsequent professionals 
reported that no help was offered (e.g., with education, therapy, or referrals to parent support groups), and only about 10% 
reported that a professional explained their child’s problems. Almost half of the families reported that the school system 
and other parents were the major source of assistance over time, rather than the medical health care community.  
 The diagnosis of autism often is not made until 2 to 3 years after symptoms are recognized, primarily because of 
concerns about labeling or incorrectly diagnosing the child. Identifying children with autism and initiating intensive, early 
intervention during the preschool years results in improved outcomes for most young children with autism.3-7 Early 
diagnosis of autism and early intervention facilitates earlier educational planning, provisions for family supports and 
education, management of family stress and anguish, and delivery of appropriate medical care and treatment.3–7  
 Clinically identifying children with autism requires two levels of investigation, each addressing a distinct component 
of patient management (figure).1 The first level, Routine Developmental Surveillance and Screening Specifically for 
Autism, should be performed on all children and involves first identifying those at risk for any type of atypical 
development, followed by identifying those specifically at risk for autism. Mental retardation or other medical or 
neurodevelopmental conditions require separate evaluations and are not within the scope of this document.  
 The second level, Diagnosis and Evaluation of Autism, involves a more in-depth investigation of already identified 
children and differentiates autism from other developmental disorders. In-depth diagnosis and evaluation are important in 
determining optimal interventional strategies based on the child’s profile of strengths and weaknesses. For these two areas 
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Refer to Early Intervention 
or Local School District 
 
Proceed to Level Two Formal Diagnostic Procedures by experienced clinician 
History & Neurological Evaluation 
Specific Evaluations to Determine Developmental Profile 
Expanded Laboratory Evaluation only if indicated
Level Two: Diagnosis and Evaluation of Autism 
Fail Pass
Refer to Level Two as indicated
Pass
Rescreen at next visit 
Laboratory investigation: 
Formal audiological assessment, Lead screen if pica present 
 
Specifically Screen for Autism: 
CHAT, Autism Screening Questionnaire 
(Australian Scale for Asperger’s Syndrome, PDDST-II-Stage 1) 
Absolute Indications for Immediate Evaluation: 
No babbling, or pointing or other gesture by 12 months 
No single words by 16 months 
No 2-word spontaneous (not echolalic) phrases by 24 months 
ANY loss of ANY language or social skills at ANY age
Level One: Routine Developmental Surveillance 
by all providers at every well-child visit e.g., PEDS, ASQ, CDIs, or BRIGANCE
Fail 
Figure. Practice parameter algorithm. 
of investigation, specific clinical questions were defined (see Appendix 2), clinical evidence was summarized, and 
diagnostic recommendations were developed.   
 Evidence and recommendations are presented in three sections. The first two sections, Level One: Routine 
Developmental Surveillance and Screening Specifically for Autism, and Level Two: Diagnosis and Evaluation of Autism, 
first present the empiric data for each question and are followed by recommendations linked to the specific evidence. 
Each is followed by a section on Recommendations for Research. The third section, Consensus-Based General Principles 
of Management, presents additional recommendations based on broad consensus. Additional information about autism, 
including behavioral aspects associated with the core defining deficits, methodology, and clinical evidence are described 
in the background paper.1 Specific information about the recommended developmental screening and diagnostic tools can 
be found at http://www.aan.com under AAN Resources: Practice Statements: Official AAN Practice Statements: Autism, 
Screening and diagnosis of. 
  
Description of the process.  Experts in the surveillance/screening and diagnosis of autism were selected by 11 
professional organizations (see Appendix 1) and convened in June 1998 and January 1999. They reviewed and evaluated 
the quality of the evidence from the published literature, developed a consensus of evidence-based management 
recommendations, and published a comprehensive background paper on the surveillance, screening, and diagnosis of 
autism.1 Evidence reviewed for this parameter was identified through literature searches using MEDLINE and 
PsychINFO. Relevant articles were included from all languages using the following search terms: autistic; OR autism; 
OR pervasive, and NOT treatment. This search produced over 4,000 citations, from which 2,750 studies met the 
following inclusion criteria: clinical papers published since 1990; review papers and meta-analyses developed for DSM-
IV; and the overview of the National Institutes of Health State of the Science Conference on Autism in 1995. Relevant 
book chapters and books were also included, as identified by the expert panel.  
 The strength of the evidence for each relevant article and book chapter was ranked using the defined criteria shown in 
Appendix 3. Recommendations were thereby derived based on the strength of the evidence and stratified (Standard, 
Guideline, or Practice Option) as defined in Appendix 3.  
 
Level one: routine developmental surveillance and screening specifically for autism.  Analysis of the evidence. When 
and how often should developmental surveillance/screening be performed?  Approximately 25% of children in any 
primary care practice show developmental issues. However, fewer than 30% of primary care providers conduct 
standardized screening tests at well-child appointments.8–10 The American Academy of Pediatrics (AAP) stresses the 
importance of a flexible, continual developmental surveillance process at each well-child visit, and recommends eliciting 
and valuing parental concerns, probing regarding age-appropriate skills in each developmental domain, and observing 
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each child.11  
 What are the appropriate developmental screening questionnaires that provide sensitive and specific information? 
Developmental screening tools have been formulated based on screening of large populations of children with 
standardized test items. Sensitive and specific developmental screening instruments include: the Ages and Stages 
Questionnaire, the BRIGANCE® Screens, the Child Development Inventories, and the Parents’ Evaluations of 
Developmental Status.1  
 The Denver-II (DDST-II, formerly the Denver Developmental Screening Test-Revised) has been the traditional tool 
used for developmental screening, but research has found that it is insensitive and lacks specificity. The Revised Denver 
Pre-Screening Developmental Questionnaire (R-DPDQ) was designed to identify a subset of children who needed further 
screening. However, studies have shown that it detected only 30% of children with language impairments and 50% of 
children with mental retardation.12–15  
 How are conventional developmental milestones defined?  Conventional developmental language milestones are 
based on normative data from numerous standardized language instruments for infants.16–19 Lack of acquisition of the 
following milestones within known accepted and established ranges is considered abnormal: no babbling by 12 months; 
no gesturing (e.g., pointing, waving bye-bye) by 12 months; no single words by 16 months; no 2-word spontaneous (not 
just echolalic) phrases by 24 months; and any loss of any language or social skills at any age. Failure to meet these 
milestones is associated with a high probability of a developmental disability.  
 Do parents provide reliable information regarding their child’s development?  Several studies encompassing 737 
children showed that parental concerns about speech and language development, behavior, or other developmental issues 
were highly sensitive (i.e., 75% to 83%) and specific (79% to 81%) in detecting global developmental deficits.20–22 
However, the absence of such concerns had modest specificity in detecting normal development (47%).20 An additional 
study that combined parental concern with a standardized parental report found this to be effective for early behavioral 
and developmental screening in the primary care setting.23  
 Can autism be reliably diagnosed before 36 months of age?  Because there are no biological markers for autism, 
screening must focus on behavior. Recent studies comparing 109 autistic and 33 typically developing children 
demonstrated that problems with eye contact, orienting to one’s name, joint attention, pretend play, imitation, nonverbal 
communication, and language development are measurable by 18 months of age.24–27 These symptoms are stable in 
children from toddler age through preschool age. Retrospective analysis of home videotapes have also identified 
behaviors that distinguish infants with autism from other developmental disabilities as early as 8 months of age.28–30  
 Current screening methods may not identify children with milder variants of autism, those without mental retardation 
or language delay, such as verbal individuals with high-functioning autism and Asperger’s disorder, or older children, 
adolescents, and young adults.  
 Is there an increased risk of having another child with autism (recurrence)?  The incidence of autism in the general 
population is 0.2%, but the risk of having a second (or additional) autistic child increases almost 50-fold to approximately 
10 to 20%.31–34  
 What tools are available with appropriate psychometric properties to specifically screen for autism?  Appropriately 
sensitive and specific autism screening tools for infants and toddlers have only recently been developed, and this 
continues to be the current focus of many research centers. The Checklist for Autism in Toddlers (CHAT) for 18-month-
old infants, and the Autism Screening Questionnaire for children 4 years of age and older, have been validated on large 
populations of children. However, it should be noted that the CHAT is less sensitive to milder symptoms of autism, as 
children later diagnosed with PDD-NOS, Asperger’s, or atypical autism did not routinely fail the CHAT at 18 months.27,35  
 The Pervasive Developmental Disorders Screening Test–II (PDDST-II) for infants from birth to 3 years of age, the 
Modified Checklist for Autism in Toddlers (M-CHAT) for infants at 2 years of age, and the Australian Scale for 
Asperger’s Syndrome for older verbal children, are currently under development or validation phases.1  
 What screening laboratory investigations are available for developmental delay, with or without suspicion of autism?  
Formal audiologic evaluation.  The Committee on Infant Hearing of the American Speech–Language–Hearing 
Association developed guidelines for the audiologic assessment of children from birth through 36 months of age.36 They 
recommended that all children with developmental delays, particularly those with delays in social and language 
development, have a formal audiologic hearing evaluation. Three studies have documented that conductive, sensorineural, 
or mixed hearing loss can co-occur with autism, and that some children with autism may be incorrectly thought to have 
peripheral hearing loss.37,38 In addition, transient conductive hearing loss associated with otitis media with effusion can 
also occur in children with autism.  
 Audiologic assessment of such children requires modifications of traditional test techniques and environments (e.g., 
operant test procedures).39,40 Electrophysiologic procedures are useful for estimating hearing sensitivity and for examining 
middle ear, cochlear, and VIIIth nerve or auditory brainstem pathway integrity.41,42 Evoked otoacoustic emissions are 
useful for examining cochlear (sensory) function, and is a frequency-specific, as well as a time- and cost-efficient 
procedure.43 Frequency-specific auditory brainstem response (ABR) is the single most useful electrophysiologic 
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procedure for use in estimating hearing thresholds, and has been demonstrated to be highly correlated with behavioral 
hearing thresholds in children who hear normally and in children who have sensorineural hearing loss.42  
 Lead screening.  Children with developmental delays who spend an extended period in the oral–motor stage of play 
(where everything "goes into their mouths") are at increased risk for lead toxicity, especially in certain environments. The 
prevalence of pica in this group can result in high rates of substantial or recurrent exposure to lead. The National Center 
for Environmental Health of the Centers for Disease Control and Prevention recommends that children with 
developmental delays, even without frank pica, should be screened for lead poisoning.44 Blood lead levels in children 
with autism are elevated.1 In one study, the mean blood lead level in 18 autistic children was higher than in 16 nonautistic 
"psychotic" children or in 10 normal siblings; 44% of the autistic and psychotic children had lead levels significantly 
above the mean compared with control subjects.45 In a more recent study, 17 autistic children treated for lead poisoning 
were compared with 30 children without autism. The autistic children were older at diagnosis, had higher lead levels, and 
most were reexposed despite close monitoring of their environment.46  
 
Level one evidence-based recommendations. 
Clinical practice recommendations.  
 
1. Developmental surveillance should be performed at all well-child visits from infancy through school-age, and at any 
age thereafter if concerns are raised about social acceptance, learning, or behavior (Guideline).  
2. Recommended developmental screening tools include the Ages and Stages Questionnaire, the BRIGANCE® 
Screens, the Child Development Inventories, and the Parents’ Evaluations of Developmental Status (Guideline).  
3. Because of the lack of sensitivity and specificity, the Denver-II (DDST-II) and the Revised Denver Pre-Screening 
Developmental Questionnaire (R-DPDQ) are not recommended for appropriate primary-care developmental 
surveillance (Guideline).  
4. Further developmental evaluation is required whenever a child fails to meet any of the following milestones 
(Guideline): babbling by 12 months; gesturing (e.g., pointing, waving bye-bye) by 12 months; single words by 16 
months; two-word spontaneous (not just echolalic) phrases by 24 months; loss of any language or social skills at any 
age.  
5. Siblings of children with autism should be carefully monitored for acquisition of social, communication, and play 
skills, and the occurrence of maladaptive behaviors. Screening should be performed not only for autism-related 
symptoms but also for language delays, learning difficulties, social problems, and anxiety or depressive symptoms 
(Guideline).  
6. Screening specifically for autism should be performed on all children failing routine developmental surveillance 
procedures using one of the validated instruments—the CHAT or the Autism Screening Questionnaire (Guideline).  
7. Laboratory investigations recommended for any child with developmental delay and/or autism include audiologic 
assessment and lead screening (Guideline). Early referral for a formal audiologic assessment should include 
behavioral audiometric measures, assessment of middle ear function, and electrophysiologic procedures using 
experienced pediatric audiologists with current audiologic testing methods and technologies (Guideline). Lead 
screening should be performed in any child with developmental delay and pica. Additional periodic screening should 
be considered if the pica persists (Guideline).  
 
 Recommendations for research. 
 
1. Develop and validate appropriate autism screening tools with adequate sensitivity and specificity in children younger 
than 1 year of age that could be used by a wide range of practitioners.  
2. Current methods of screening for autism may not identify: 1) children with milder variants of the disorder; 2) 
children without mental retardation or language delay, such as verbal individuals with high functioning autism and 
Asperger’s disorder; or 3) older children, adolescents, and young adults. Additional tools are needed to help identify 
and evaluate these groups of patients.  
3. Studies are needed to provide insight into the emergence of early auditory behaviors that are considered atypical and 
may be prevalent in children with autism. Studies are also needed on the audiologic characteristics of individuals 
with autism to help assess peripheral hearing sensitivity and suprathreshold responses.  
 
Level two: diagnosis and evaluation of autism.  Analysis of the evidence.  Who should diagnose autism?  Although 
educators, parents, and other health care professionals identify signs and symptoms characteristic of autism, a clinician 
experienced in the diagnosis and treatment of autism is usually necessary for accurate and appropriate diagnosis.25,47,48 
Clinicians must rely on their clinical judgment, aided by guides to diagnosis, such as DSM-IV and the Tenth Edition of 
the International Classification of Diseases (ICD-10), as well as by the results of various assessment instruments, rating 
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scales, and checklists. These instruments and criteria should be used by practitioners not as experienced in the diagnosis 
of autism.  
 What are the medical and neurologic concerns in evaluating children with autism?  Familial prevalence.  Family 
studies have shown that there is a 50-fold to 100-fold increase in the rate of autism in first-degree relatives of autistic 
children. Within these families, there are also elevated rates of social difficulties; higher incidences of cognitive, 
communication, learning and executive function deficits; increased stereotyped behaviors; and anxiety, affective, 
language, and pragmatic disorders.33,49–55 Monozygotic twin pair studies have also shown a high concordance rate (60%) 
for DSM-IV Autistic Disorder, 71% for the broader autistic spectrum phenotype, and 92% for an even broader phenotype 
of social and communication deficits with stereotyped behaviors that nonetheless were clearly differentiated from normal. 
In contrast, no concordance for autism was noted in dizygotic twin pairs and only 10% were concordant for some form of 
cognitive, social or language deficit.56,57  
 Large head circumference without frank neuropathology.  Children with autism have a larger head circumference; 
only a small proportion have frank macrocephaly.33,57–61 Large head size may not necessarily be present at birth, but may 
appear in early to mid-childhood, perhaps indicating an increased rate of brain growth. Neuroimaging studies in autism 
also found larger brain volumes without associated neuropathology.62,63  
 Association with tuberous sclerosis complex (TSC) and less often with Fragile X (FraX) syndrome.  Seventeen to 
over 60% of mentally retarded individuals with TSC are also autistic, and these patients commonly have epilepsy.64–67 In 
contrast, the number of autistic individuals with TSC has been estimated to be between 0.4% and 3%.66 This rate 
increases to 8% to 14% if epilepsy is also present.66  
 Clinical studies report that 3% to 25% of patients with FraX have autism.68–70 However, no evidence of FraX in 
autistic individuals was found using cytogenetic (not DNA analysis) techniques;71 with molecular genetic analyses, only a 
few autistic individuals were shown to have FraX.72  
 What are the specific deficits of the autistic child’s developmental profile?  Speech, language, and verbal and 
nonverbal communication.  Verbal and nonverbal communication deficits seen in autism are far more complex than 
simple speech delay, but overlap with developmental language disorders or specific language impairments. Expressive 
language function ranges from complete mutism (as often seen in children 2 to 3 years of age) to verbal fluency, though 
verbal abilities are often accompanied by many errors in word meaning (semantics) or language and communicative 
deficits in social contexts (social-pragmatics).73–75  
 Cognitive deficits.  Many autistic individuals demonstrate a particular pattern on intellectual tests that is characteristic 
of autism, i.e., performance IQ (PIQ) higher than verbal IQ (VIQ), and specific intersubtest scatter, with Block Design 
typically the highest subtest and Comprehension usually the lowest. However, the PIQ–VIQ split is severity dependent. 
When Full Scale IQ (FSIQ) and VIQ are both above 70, 80% of autistic individuals will have no significant VIQ–PIQ 
disparity, and the remainder are evenly divided between those with PIQ > VIQ and those with PIQ < VIQ.76  
 The DSM-IV defines the diagnosis of mental retardation as the combination of subaverage intellectual functioning 
(IQ < 70) and concurrent deficits in adaptive functioning. Autistic individuals have poorer adaptive function than would 
be predicted by IQ alone.77  
 Sensorimotor deficits.  Impairments of gross and fine motor function are reported as being common in autistic 
individuals, and are recognized as hypotonia, limb apraxia, or motor stereotypies. Motor deficits are more severe in 
individuals with lower IQ scores.78 Hand or finger mannerisms, body rocking, or unusual posturing are reported in 37% to 
95% of individuals, and often manifest during the preschool years.24,58,78 Sensory processing abilities are aberrant in 42% 
to 88% of autistic individuals and include preoccupation with sensory features of objects, over- or underresponsiveness to 
environmental stimuli, or paradoxical responses to sensory stimuli.79  
 Neuropsychological, behavioral, and academic impairments.  Specific neuropsychological impairments can be 
identified, even in young children with autism, that correlate with the severity of autistic symptoms.80 Performance on 
tasks that rely on rote, mechanical, or perceptual processes are typically spared; deficient performance exists on tasks 
requiring higher-order conceptual processes, reasoning, interpretation, integration, or abstraction. Dissociations between 
simple and complex processing are reported in the areas of language, memory, executive function, motor function, 
reading, mathematics, and perspective-taking.80–83 There is no reported evidence that confirms or excludes a diagnosis of 
autism based on these cognitive patterns alone.  
 When and what laboratory investigations are indicated for the diagnosis of autism?  Genetic testing.  A chromosomal 
abnormality reported in possibly more than 1% of autistic individuals involves the proximal long arm of chromosome 15 
(15q11-q13), which is a greater frequency than other currently identifiable chromosomal disorders.84–86 Those with the 
15q abnormalities typically have moderate to profound mental retardation. The duplication is usually maternally 
inherited, either pseudodicentric 15 (inverted duplication 15) or other atypical marker chromosomes, with one or two 
extra copies of the area roughly corresponding to the typical Angelman syndrome (AS)/Prader Willi Syndrome (PWS) 
deletion region of approximately four million base pairs. Conversely, AS is usually due to a deletion of maternally 
inherited 15q11-q13 material and has been found in patients with autism and profound mental retardation.85,87  
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 Metabolic testing.  Inborn errors in amino acid, carbohydrate, purine, peptide, and mitochondrial metabolism, as well 
as toxicologic studies have been studied, but the percentage of children with autism who have a metabolic disorder is 
probably less (and some experts agree that it is considerably less) than 5%.88,89  
 Electrophysiologic testing.  The prevalence of epilepsy in autistic children has been estimated at 790 to 14%,91 
whereas the cumulative prevalence by adulthood is estimated at 20% to 35%.90,91 Seizure onset peaks in early childhood 
and again in adolescence. Mental retardation, with or without motor abnormalities and family history of epilepsy, was a 
significant risk factor for the development of seizures in autistic individuals.92–95  
 It is unclear whether there is a relationship between autism and an early regressive course (before 36 months), 
childhood disintegrative disorder ([CDD] after 36 months), Landau–Kleffner syndrome, and electrical status epilepticus 
during slow wave sleep (ESES). Autism with regression and CDD have both been associated with seizures or 
epileptiform sleep-deprived EEG (with adequate sampling of slow wave sleep).96–98 A higher incidence of epileptiform 
EEG abnormalities in autistic children with a history of regression has been reported when compared to autistic children 
with clinical epilepsy.97 Seizures or epileptiform discharges were more prevalent in children with regression who 
demonstrated cognitive deficits. Regression in cognition and language in adolescence associated with seizure onset has 
also been observed, but little is known about its cause or prevalence. There may be a causal relationship between a 
subgroup of children with autistic regression and EEG-defined "benign focal epilepsies."99 There is insufficient evidence 
to suggest a role for event-related potentials or magnetoencephalography in the evaluation of autism.  
 Neuroimaging.  CT studies, ordered as standard assessments of children diagnosed with autism during the 1970s and 
1980s, reported a wide range of brain imaging abnormalities and suggested that there was an underlying structural 
disorder in patients with autism. This view changed when Damasio et al.100 demonstrated that such abnormalities were 
incidental to coexisting anatomic disorders unrelated to autism. A very low prevalence of focal lesions or other structural 
abnormalities was found; their inconsistent localization marked them as coincidental. Prevalence of lesions on MRI in 
children with autism is similar to normal control subjects.101 CT and MRI studies of autistic subjects screened to exclude 
those with disorders other than autism confirmed the absence of significant structural brain abnormalities.63  
 Functional imaging modalities such as functional MRI (fMRI), single-photon emission CT (SPECT), or positron-
emission tomography (PET) are currently only research tools in the evaluation of autism. There is no evidence to support 
a role for functional neuroimaging studies in the clinical diagnosis of autism at the present time.1 
 Other tests.  There is insufficient evidence to support the use of other tests such as hair analysis for trace elements, 
celiac antibodies, allergy testing (particularly food allergies for gluten, casein, candida, and other molds), immunologic or 
neurochemical abnormalities, micronutrients such as vitamin levels, intestinal permeability studies, stool analysis, urinary 
peptides, mitochondrial disorders (including lactate and pyruvate), thyroid function tests, or erythrocyte glutathione 
peroxidase studies.1  
 
Level two: evidence-based recommendations.   
Clinical practice recommendations. 
 
1. Genetic testing in children with autism, specifically high resolution chromosome studies (karyotype) and DNA 
analysis for FraX, should be performed in the presence of mental retardation (or if mental retardation cannot be 
excluded), if there is a family history of FraX or undiagnosed mental retardation, or if dysmorphic features are 
present (Standard). However, there is little likelihood of positive karyotype or FraX testing in the presence of high-
functioning autism.  
2. Selective metabolic testing (Standard) should be initiated by the presence of suggestive clinical and physical 
findings such as the following: if lethargy, cyclic vomiting, or early seizures are evident; the presence of dysmorphic 
or coarse features; evidence of mental retardation or if mental retardation cannot be ruled out; or if occurrence or 
adequacy of newborn screening for a birth is questionable.  
3. There is inadequate evidence at the present time to recommend an EEG study in all individuals with autism. 
Indications for an adequate sleep-deprived EEG with appropriate sampling of slow wave sleep include (Guideline) 
clinical seizures or suspicion of subclinical seizures, and a history of regression (clinically significant loss of social 
and communicative function) at any age, but especially in toddlers and preschoolers.  
4. Recording of event-related potentials and magnetoencephalography are research tools at the present time, without 
evidence of routine clinical utility (Guideline).  
5. There is no clinical evidence to support the role of routine clinical neuroimaging in the diagnostic evaluation of 
autism, even in the presence of megalencephaly (Guideline).  
6. There is inadequate supporting evidence for hair analysis, celiac antibodies, allergy testing (particularly food allergies 
for gluten, casein, candida, and other molds), immunologic or neurochemical abnormalities, micronutrients such as 
vitamin levels, intestinal permeability studies, stool analysis, urinary peptides, mitochondrial disorders (including 
lactate and pyruvate), thyroid function tests, or erythrocyte glutathione peroxidase studies (Guideline).  
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 Recommendations for research. 
 
1. Studies are needed to further identify the usefulness of electrophysiologic techniques to clarify the role of epilepsy in 
autism, especially in children with a history of regression.  
2. Additional studies to examine potential genetic and/or environmental factors and their relationship to the etiology of 
autism are needed.  
3. Continuing efforts might focus on identifying contributing genes to determine whether the behavioral syndromes 
(which constitute the basis of DSM-IV and ICD-10) have actual biological validity.  
4. Evaluation of environmental factors (e.g., nonspecific infections or other immunologically mediated events) that 
might contribute to triggering the expression of autistic symptoms or regression requires additional study.  
 
Consensus-based general principles of management.  The following recommendations are based on consensus 
agreement by the participating organizations involved in the development of this parameter.1 
 Surveillance and screening.  In the United States, states must follow federal Public Law 105-17: the Individuals with 
Disabilities Education Act Amendments of 1997–IDEA’97, which mandates immediate referral for a free appropriate 
public education for eligible children with disabilities from the age of 36 months, and early intervention services for 
infants and toddlers with disabilities from birth through 35 months of age.  
 Diagnosis.  The diagnosis of autism should include the use of a diagnostic instrument with at least moderate 
sensitivity and good specificity for autism. Sufficient time should be planned for standardized parent interviews regarding 
current concerns and behavioral history related to autism, and direct, structured observation of social and communicative 
behavior and play. Recommended instruments include1:  
 
Diagnostic parental interviews  
The Gilliam Autism Rating Scale  
The Parent Interview for Autism  
The Pervasive Developmental Disorders Screening Test–Stage 3  
The Autism Diagnostic Interview–Revised  
 
Diagnostic observation instruments  
The Childhood Autism Rating Scale  
The Screening Tool for Autism in Two-Year-Olds  
The Autism Diagnostic Observation Schedule-Generic  
 
 Medical and neurologic evaluation.  Perinatal and developmental history should include milestones; regression in 
early childhood or later in life; encephalopathic events; attentional deficits; seizure disorder (absence or generalized); 
depression or mania; and behaviors such as irritability, self-injury, sleep and eating disturbances, and pica. The physical 
and neurologic examination should include: longitudinal measurements of head circumference and examination for 
unusual features (facial, limb, stature, etc.) suggesting the need for genetic evaluation; neurocutaneous abnormalities 
(requiring an ultraviolet [Wood’s] lamp examination); gait; tone; reflexes; cranial nerves; and determination of mental 
status, including verbal and nonverbal language and play.  
 Evaluation and monitoring of autism.  The immediate and long-term evaluation and monitoring of autistic individuals 
requires a comprehensive multidisciplinary approach, and can include one or more of the following professionals: 
psychologists, neurologists, speech–language pathologists and audiologists, pediatricians, child psychiatrists, 
occupational therapists, and physical therapists, as well as educators and special educators. Individuals with mild autism 
should also receive adequate assessments and appropriate diagnoses.  
 Reevaluation within 1 year of initial diagnosis and continued monitoring is an expected aspect of clinical practice 
because relatively small changes in the developmental level affect the impact of autism in the preschool years. In general, 
there is no need to repeat extensive diagnostic testing; however, follow-up visits can be helpful to address behavioral, 
environmental, and other developmental concerns.  
 Speech, language, and communication evaluation.  A comprehensive speech–language–communication evaluation 
should be performed on all children who fail language developmental screening procedures by a speech–language 
pathologist with training and expertise in evaluating children with developmental disabilities. Comprehensive 
assessments of both preverbal and verbal individuals should account for age, cognitive level, and socioemotional abilities, 
and should include assessment of receptive language and communication, expressive language and communication, voice 
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and speech production, and in verbal individuals, a collection and analysis of spontaneous language samples to 
supplement scores on formal language tests.  
 Cognitive and adaptive behavior evaluations.  Cognitive evaluations should be performed in all children with autism 
by a psychologist or other trained professional. Cognitive instruments should be appropriate for the mental and 
chronologic age, provide a full range (in the lower direction) of standard scores and current norms independent of social 
ability, include independent measures of verbal and nonverbal abilities, and provide an overall index of ability. A measure 
of adaptive functioning should be collected for any child evaluated for an associated cognitive handicap. Consensus-based 
recommendations for using specific instruments include the Vineland Adaptive Behavior Scales and the Scales of 
Independent Behavior–Revised.1  
 Sensorimotor and occupational therapy evaluations.  Evaluation of sensorimotor skills by a qualified experienced 
professional (occupational therapist or physical therapist) should be considered, including assessment of gross and fine 
motor skills, praxis, sensory processing abilities, unusual or stereotyped mannerisms, and the impact of these components 
on the autistic person’s life. An occupational therapy evaluation is indicated when deficits exist in functional skills or 
occupational performance in the areas of play or leisure, self-maintenance through activities of daily living, or productive 
school and work tasks. Although not routinely warranted as part of all evaluations of children with autism, the Sensory 
Integration and Praxis Tests may be used on an individual basis to detect specific patterns of sensory integrative 
dysfunction.  
 Neuropsychological, behavioral, and academic assessments.  These assessments should be performed as needed, in 
addition to the cognitive assessment, to include social skills and relationships, educational functioning, problematic 
behaviors, learning style, motivation and reinforcement, sensory functioning, and self-regulation. Assessment of family 
resources should be performed by appropriate psychologists or other qualified health care professionals and should 
include assessment of parents’ level of understanding of their child’s condition, family (parent and sibling) strengths, 
talents, stressors and adaptation, resources and supports, as well as offer appropriate counseling and education.  
 
Disclaimer.  The Quality Standards Subcommittee (QSS) of the American Academy of Neurology (AAN) seeks to 
develop scientifically sound, clinically relevant practice parameters for the practice of neurology. Practice parameters are 
strategies for patient management that assist physicians in clinical decision making. A practice parameter is one or more 
specific recommendations based on analysis of evidence of a specific clinical problem. These might include diagnosis, 
symptoms, treatment, or procedure evaluation. This evidence-based review addresses the major management issues health 
care providers face in surveying, screening, and diagnosing children with autism. The clinical evidence is reviewed, 
management recommendations provided, and areas of continued research identified. This statement is provided as an 
educational service of the American Academy of Neurology. It is based on an assessment of current scientific and clinical 
information. It is not intended to include all possible proper methods of care for choosing to use a specific procedure. 
Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care 
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Appendix 2 
Clinical questions addressed for surveillance, screening and diagnosing children with autism  
 Routine developmental surveillance and screening for autism  
1. When and how often should developmental surveillance/screening be performed?  
2. What are the appropriate developmental screening questionnaires that provide sensitive and specific information?  
3. How are conventional developmental milestones defined?  
4. Do parents provide reliable information regarding their child’s development?  
5. Can autism can be reliably diagnosed before 36 months of age?  
6. Is there an increased risk of having another child with autism (recurrence)?  
7. What screening laboratory investigations are available for developmental delay, with or without suspicion of autism?  
8. What tools are available with appropriate psychometric properties to specifically screen for autism?  
 
 Diagnosis and evaluation of autism  
1. Who should diagnose autism?  
2. What are the medical and neurologic concerns in evaluating children with autism?  
3. What are the specific deficits of the autistic child’s developmental profile?  
4. When and what laboratory investigations are indicated for the diagnosis of autism?  
 
Appendix 3   
Definitions for strength of the evidence  
 Class I. Must have all of a through d. a) Prospective study of a well-defined cohort which includes a description of the nature of 
the population, the inclusion/exclusion criteria, demographic characteristics such as age and sex, and seizure type. b) The sample size 
must be adequate with enough statistical power to justify a conclusion or for identification of subgroups for whom testing does or does 
not yield significant information. c) The interpretation of evaluations performed must be done blinded to outcome. d) There must be a 
satisfactory description of the technology used for evaluations (e.g., EEG, MRI).  
 Class II. Must have a or b. a) Retrospective study of a well-defined cohort which otherwise meets criteria for class 1a, b and 1d. b) 
Prospective or retrospective study which lacks any of the following: adequate sample size, adequate methodology, a description of 
inclusion/exclusion criteria, and information such as age, sex and characteristics of the seizure.  
 Class III. Must have a or b. a) A small cohort or case report. b) Relevant expert opinion, consensus, or survey.  
 A cost-benefit analysis or a meta-analysis may be class I, II, or III, depending on the strength of the data upon which the analysis 
is based.  
 
Definitions for strength of the recommendations 
 Standard. A principle for patient management that reflects a high degree of clinical certainty (usually requires one or more Class I 
studies that directly address the clinical question, or overwhelming Class II evidence when circumstances preclude randomized clinical 
trials).  
 Guideline. A recommendation for patient management that reflects moderate clinical certainty (usually requires one or more Class 
II studies or a strong consensus of Class III evidence).  
 Practice option. Strategy for patient management for which clinical utility is uncertain (inconclusive or conflicting evidence or 
opinion).  
 
Appendix 4   
American Academy of Neurology Quality Standards Subcommittee Members: Gary Franklin, MD, MPH—Co-Chair; Catherine A. 
Zahn, MD—Co-Chair; Milton Alter, MD, PhD; Stephen Ashwal, MD (facilitator); John Calverley, MD; Richard Dubinsky, MD; 
Jacqueline French, MD; Michael Glantz, MD; Michael K. Greenberg, MD; Gary Gronseth, MD; Deborah Hirtz, MD; Robert G. Miller, 
MD; James Stevens, MD; William Weiner, MD; and Wendy Edlund, AAN Manager, Clinical Practice Guidelines.  
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